Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 241

1.

Effectiveness and Safety of Therapeutic Regimens for Elderly Patients With Acute Myeloid Leukemia: A Systematic Literature Review.

Bell JA, Galaznik A, Huelin R, Stokes M, Guo Y, Fram RJ, Faller DV.

Clin Lymphoma Myeloma Leuk. 2018 May 10. pii: S2152-2650(18)30131-9. doi: 10.1016/j.clml.2018.05.003. [Epub ahead of print] Review.

2.

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.

Lockhart AC, Bauer TM, Aggarwal C, Lee CB, Harvey RD, Cohen RB, Sedarati F, Nip TK, Faessel H, Dash AB, Dezube BJ, Faller DV, Dowlati A.

Invest New Drugs. 2018 May 21. doi: 10.1007/s10637-018-0610-0. [Epub ahead of print]

PMID:
29781056
3.

Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.

Bell JA, Galaznik A, Huelin R, Stokes M, Guo Y, Fram RJ, Faller DV.

Clin Lymphoma Myeloma Leuk. 2018 Apr;18(4):e157-e166. doi: 10.1016/j.clml.2018.02.001. Epub 2018 Feb 8. Review.

4.

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML.

Swords RT, Coutre S, Maris MB, Zeidner JF, Foran JM, Cruz J, Erba HP, Berdeja JG, Tam W, Vardhanabhuti S, Pawlikowska-Dobler I, Faessel HM, Dash AB, Sedarati F, Dezube BJ, Faller DV, Savona MR.

Blood. 2018 Mar 29;131(13):1415-1424. doi: 10.1182/blood-2017-09-805895. Epub 2018 Jan 18.

5.

Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis.

Hari P, Lin HM, Asche CV, Ren J, Yong C, Luptakova K, Faller DV, Sanchorawala V.

Amyloid. 2018 Mar;25(1):1-7. doi: 10.1080/13506129.2017.1411796. Epub 2018 Jan 5.

PMID:
29303358
6.

Epigenetic Treatment of Neurodegenerative Ophthalmic Disorders: An Eye Toward the Future.

Moos WH, Faller DV, Glavas IP, Harpp DN, Irwin MH, Kanara I, Pinkert CA, Powers WR, Steliou K, Vavvas DG, Kodukula K.

Biores Open Access. 2017 Dec 1;6(1):169-181. doi: 10.1089/biores.2017.0036. eCollection 2017. Review.

7.

Gut Microbiota and Salivary Diagnostics: The Mouth Is Salivating to Tell Us Something.

Kodukula K, Faller DV, Harpp DN, Kanara I, Pernokas J, Pernokas M, Powers WR, Soukos NS, Steliou K, Moos WH.

Biores Open Access. 2017 Oct 1;6(1):123-132. doi: 10.1089/biores.2017.0020. eCollection 2017. Review.

8.

Disease burden of systemic light-chain amyloidosis: a systematic literature review.

Lin HM, Gao X, Cooke CE, Berg D, Labotka R, Faller DV, Seal B, Hari P.

Curr Med Res Opin. 2017 Jun;33(6):1017-1031. doi: 10.1080/03007995.2017.1297930. Epub 2017 Apr 11. Review.

PMID:
28277869
9.

An oral HemokineTM, α-methylhydrocinnamate, enhances myeloid and neutrophil recovery following irradiation in vivo.

Faller DV, Castaneda SA, Zhou D, Vedamony M, Newburger PE, White GL, Kosanke S, Plett PA, Orschell CM, Boosalis MS, Perrine SP.

Blood Cells Mol Dis. 2017 Mar;63:1-8. doi: 10.1016/j.bcmd.2016.10.021. Epub 2016 Oct 31.

10.

Epigenetic Treatment of Persistent Viral Infections.

Moos WH, Pinkert CA, Irwin MH, Faller DV, Kodukula K, Glavas IP, Steliou K.

Drug Dev Res. 2017 Feb;78(1):24-36. doi: 10.1002/ddr.21366. Epub 2016 Oct 20. Review.

PMID:
27761936
11.

Microbiota and Neurological Disorders: A Gut Feeling.

Moos WH, Faller DV, Harpp DN, Kanara I, Pernokas J, Powers WR, Steliou K.

Biores Open Access. 2016 May 1;5(1):137-45. doi: 10.1089/biores.2016.0010. eCollection 2016. Review. Erratum in: Biores Open Access. 2017 May 01;6(1):46.

12.

Epigenetic Treatment of Neuropsychiatric Disorders: Autism and Schizophrenia.

Moos WH, Maneta E, Pinkert CA, Irwin MH, Hoffman ME, Faller DV, Steliou K.

Drug Dev Res. 2016 Mar;77(2):53-72. doi: 10.1002/ddr.21295. Epub 2016 Feb 21. Review.

PMID:
26899191
13.

Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases.

Irwin MH, Moos WH, Faller DV, Steliou K, Pinkert CA.

Drug Dev Res. 2016 May;77(3):109-23. doi: 10.1002/ddr.21294. Epub 2016 Feb 21. Review.

PMID:
26899010
14.

Novel Inducers of Fetal Globin Identified through High Throughput Screening (HTS) Are Active In Vivo in Anemic Baboons and Transgenic Mice.

Boosalis MS, Sangerman JI, White GL, Wolf RF, Shen L, Dai Y, White E, Makala LH, Li B, Pace BS, Nouraie M, Faller DV, Perrine SP.

PLoS One. 2015 Dec 29;10(12):e0144660. doi: 10.1371/journal.pone.0144660. eCollection 2015.

15.

Therapeutic fetal-globin inducers reduce transcriptional repression in hemoglobinopathy erythroid progenitors through distinct mechanisms.

Dai Y, Sangerman J, Luo HY, Fucharoen S, Chui DH, Faller DV, Perrine SP.

Blood Cells Mol Dis. 2016 Jan;56(1):62-9. doi: 10.1016/j.bcmd.2015.10.004. Epub 2015 Oct 27.

16.

The E3 ligase APC/C(Cdh1) promotes ubiquitylation-mediated proteolysis of PAX3 to suppress melanocyte proliferation and melanoma growth.

Cao J, Dai X, Wan L, Wang H, Zhang J, Goff PS, Sviderskaya EV, Xuan Z, Xu Z, Xu X, Hinds P, Flaherty KT, Faller DV, Goding CR, Wang Y, Wei W, Cui R.

Sci Signal. 2015 Sep 1;8(392):ra87. doi: 10.1126/scisignal.aab1995.

PMID:
26329581
17.

Bioprotective carnitinoids: lipoic acid, butyrate, and mitochondria-targeting to treat radiation injury: mitochondrial drugs come of age.

Steliou K, Faller DV, Pinkert CA, Irwin MH, Moos WH.

Drug Dev Res. 2015 Jun;76(4):167-75. doi: 10.1002/ddr.21258.

PMID:
26109467
18.

Identification of a novel polyprenylated acylphloroglucinol‑derived SIRT1 inhibitor with cancer‑specific anti-proliferative and invasion-suppressing activities.

Zhu L, Qi J, Chiao CY, Zhang Q, Porco JA Jr, Faller DV, Dai Y.

Int J Oncol. 2014 Nov;45(5):2128-36. doi: 10.3892/ijo.2014.2639. Epub 2014 Sep 3.

19.

SIRT1 inactivation evokes antitumor activities in NSCLC through the tumor suppressor p27.

Zhu L, Chiao CY, Enzer KG, Stankiewicz AJ, Faller DV, Dai Y.

Mol Cancer Res. 2015 Jan;13(1):41-9. doi: 10.1158/1541-7786.MCR-14-0239. Epub 2014 Aug 20.

20.

Targeted fetal hemoglobin induction for treatment of beta hemoglobinopathies.

Perrine SP, Pace BS, Faller DV.

Hematol Oncol Clin North Am. 2014 Apr;28(2):233-48. doi: 10.1016/j.hoc.2013.11.009. Review.

PMID:
24589264
21.

Protein kinase C-δ inactivation inhibits the proliferation and survival of cancer stem cells in culture and in vivo.

Chen Z, Forman LW, Williams RM, Faller DV.

BMC Cancer. 2014 Feb 14;14:90. doi: 10.1186/1471-2407-14-90.

22.

Protein kinase Cδ is a therapeutic target in malignant melanoma with NRAS mutation.

Takashima A, English B, Chen Z, Cao J, Cui R, Williams RM, Faller DV.

ACS Chem Biol. 2014 Apr 18;9(4):1003-14. doi: 10.1021/cb400837t. Epub 2014 Feb 18.

23.

MicroRNA let-7 downregulates STAT3 phosphorylation in pancreatic cancer cells by increasing SOCS3 expression.

Patel K, Kollory A, Takashima A, Sarkar S, Faller DV, Ghosh SK.

Cancer Lett. 2014 May 28;347(1):54-64. doi: 10.1016/j.canlet.2014.01.020. Epub 2014 Jan 31.

24.

Enhanced cytotoxicity from deoxyguanosine-enriched T-oligo in prostate cancer cells.

Rankin AM, Forman L, Sarkar S, Faller DV.

Nucleic Acid Ther. 2013 Oct;23(5):311-21. doi: 10.1089/nat.2013.0420. Epub 2013 Aug 24.

25.

Telomere-homologous G-rich oligonucleotides sensitize human ovarian cancer cells to TRAIL-induced growth inhibition and apoptosis.

Sarkar S, Faller DV.

Nucleic Acid Ther. 2013 Jun;23(3):167-74. doi: 10.1089/nat.2012.0401. Epub 2013 May 2.

26.

Butyrate histone deacetylase inhibitors.

Steliou K, Boosalis MS, Perrine SP, Sangerman J, Faller DV.

Biores Open Access. 2012 Aug;1(4):192-8. doi: 10.1089/biores.2012.0223.

27.

Targeting the RAS oncogene.

Takashima A, Faller DV.

Expert Opin Ther Targets. 2013 May;17(5):507-31. doi: 10.1517/14728222.2013.764990. Epub 2013 Jan 30. Review.

28.

SIRT1 represses estrogen-signaling, ligand-independent ERα-mediated transcription, and cell proliferation in estrogen-responsive breast cells.

Moore RL, Faller DV.

J Endocrinol. 2013 Feb 15;216(3):273-85. doi: 10.1530/JOE-12-0102. Print 2013 Mar.

29.

SIRT1 enhances matrix metalloproteinase-2 expression and tumor cell invasion in prostate cancer cells.

Lovaas JD, Zhu L, Chiao CY, Byles V, Faller DV, Dai Y.

Prostate. 2013 Apr;73(5):522-30. doi: 10.1002/pros.22592. Epub 2012 Oct 4.

30.

Advances in Virus-Directed Therapeutics against Epstein-Barr Virus-Associated Malignancies.

Ghosh SK, Perrine SP, Faller DV.

Adv Virol. 2012;2012:509296. doi: 10.1155/2012/509296. Epub 2012 Mar 5.

31.

SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis.

Byles V, Zhu L, Lovaas JD, Chmilewski LK, Wang J, Faller DV, Dai Y.

Oncogene. 2012 Oct 25;31(43):4619-29. doi: 10.1038/onc.2011.612. Epub 2012 Jan 16.

32.

Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents.

Ghosh SK, Perrine SP, Williams RM, Faller DV.

Blood. 2012 Jan 26;119(4):1008-17. doi: 10.1182/blood-2011-06-362434. Epub 2011 Dec 7.

33.

Sirtuin 1 (SIRT1) and steroid hormone receptor activity in cancer.

Moore RL, Dai Y, Faller DV.

J Endocrinol. 2012 Apr;213(1):37-48. doi: 10.1530/JOE-11-0217. Epub 2011 Dec 12. Review.

34.

Protein kinase Cδ inactivation inhibits cellular proliferation and decreases survival in human neuroendocrine tumors.

Chen Z, Forman LW, Miller KA, English B, Takashima A, Bohacek RA, Williams RM, Faller DV.

Endocr Relat Cancer. 2011 Dec 1;18(6):759-71. doi: 10.1530/ERC-10-0224. Print 2011 Dec.

35.

Mechanism of T-oligo-induced cell cycle arrest in Mia-PaCa pancreatic cancer cells.

Rankin AM, Sarkar S, Faller DV.

J Cell Physiol. 2012 Jun;227(6):2586-94. doi: 10.1002/jcp.22997.

36.

Histone deacetylase inhibitors reverse CpG methylation by regulating DNMT1 through ERK signaling.

Sarkar S, Abujamra AL, Loew JE, Forman LW, Perrine SP, Faller DV.

Anticancer Res. 2011 Sep;31(9):2723-32.

PMID:
21868513
37.

Novel therapeutic candidates, identified by molecular modeling, induce γ-globin gene expression in vivo.

Boosalis MS, Castaneda SA, Trudel M, Mabaera R, White GL, Lowrey CH, Emery DW, Mpollo MS, Shen L, Wargin WA, Bohacek R, Faller DV, Perrine SP.

Blood Cells Mol Dis. 2011 Aug 15;47(2):107-16. doi: 10.1016/j.bcmd.2011.04.008.

38.

Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteers.

Perrine SP, Wargin WA, Boosalis MS, Wallis WJ, Case S, Keefer JR, Faller DV, Welch WC, Berenson RJ.

J Clin Pharmacol. 2011 Aug;51(8):1186-94. doi: 10.1177/0091270010379810. Epub 2011 Mar 21.

39.

T-oligos inhibit growth and induce apoptosis in human ovarian cancer cells.

Sarkar S, Faller DV.

Oligonucleotides. 2011 Feb;21(1):47-53. doi: 10.1089/oli.2010.0259. Epub 2011 Jan 31.

40.

A vitamin D receptor-alkylating derivative of 1α,25-dihydroxyvitamin D3 inhibits growth of human kidney cancer cells and suppresses tumor growth.

Lambert JR, Eddy VJ, Young CD, Persons KS, Sarkar S, Kelly JA, Genova E, Lucia MS, Faller DV, Ray R.

Cancer Prev Res (Phila). 2010 Dec;3(12):1596-607. doi: 10.1158/1940-6207.CAPR-10-0122.

41.

A randomized phase II trial of Arginine Butyrate with standard local therapy in refractory sickle cell leg ulcers.

McMahon L, Tamary H, Askin M, Adams-Graves P, Eberhardt RT, Sutton M, Wright EC, Castaneda SA, Faller DV, Perrine SP.

Br J Haematol. 2010 Dec;151(5):516-24. doi: 10.1111/j.1365-2141.2010.08395.x. Epub 2010 Oct 19.

PMID:
20955402
42.

Aberrant cytoplasm localization and protein stability of SIRT1 is regulated by PI3K/IGF-1R signaling in human cancer cells.

Byles V, Chmilewski LK, Wang J, Zhu L, Forman LW, Faller DV, Dai Y.

Int J Biol Sci. 2010 Oct 7;6(6):599-612.

43.

Fetal globin gene inducers: novel agents and new potential.

Perrine SP, Castaneda SA, Chui DH, Faller DV, Berenson RJ, Siritanaratku N, Fucharoen S.

Ann N Y Acad Sci. 2010 Aug;1202:158-64. doi: 10.1111/j.1749-6632.2010.05593.x.

44.

HIC1 regulates tumor cell responses to endocrine therapies.

Zhang B, Faller DV, Wang S.

Mol Endocrinol. 2009 Dec;23(12):2075-85. doi: 10.1210/me.2009-0231. Epub 2009 Oct 9. Retraction in: Mol Endocrinol. 2011 Sep;25(9):1676.

45.

Development of a malignancy-associated proteomic signature for diffuse large B-cell lymphoma.

Romesser PB, Perlman DH, Faller DV, Costello CE, McComb ME, Denis GV.

Am J Pathol. 2009 Jul;175(1):25-35. doi: 10.2353/ajpath.2009.080707. Epub 2009 Jun 4.

46.

Identification of LTR-specific small non-coding RNA in FeLV infected cells.

Forman LW, Pal-Ghosh R, Spanjaard RA, Faller DV, Ghosh SK.

FEBS Lett. 2009 Apr 17;583(8):1386-90. doi: 10.1016/j.febslet.2009.03.056. Epub 2009 Mar 29.

47.

Erythroid Kruppel-like factor (EKLF) is recruited to the gamma-globin gene promoter as a co-activator and is required for gamma-globin gene induction by short-chain fatty acid derivatives.

Perrine SP, Mankidy R, Boosalis MS, Bieker JJ, Faller DV.

Eur J Haematol. 2009 Jun;82(6):466-76. doi: 10.1111/j.1600-0609.2009.01234.x. Epub 2009 Feb 5.

48.

PKCdelta survival signaling in cells containing an activated p21Ras protein requires PDK1.

Xia S, Chen Z, Forman LW, Faller DV.

Cell Signal. 2009 Apr;21(4):502-8. doi: 10.1016/j.cellsig.2008.12.002. Epub 2008 Dec 10.

49.

Requirement for chromatin-remodeling complex in novel tumor suppressor HIC1-mediated transcriptional repression and growth control.

Zhang B, Chambers KJ, Leprince D, Faller DV, Wang S.

Oncogene. 2009 Feb 5;28(5):651-61. doi: 10.1038/onc.2008.419. Epub 2008 Nov 17. Retraction in: Oncogene. 2011 Oct 20;30(42):4374.

50.

Telomere homolog oligonucleotides induce apoptosis in malignant but not in normal lymphoid cells: mechanism and therapeutic potential.

Longe HO, Romesser PB, Rankin AM, Faller DV, Eller MS, Gilchrest BA, Denis GV.

Int J Cancer. 2009 Jan 15;124(2):473-82. doi: 10.1002/ijc.23946.

Supplemental Content

Loading ...
Support Center